

*CHL-102(C);**Amendment for S/N 10/790,647, responsive to Restriction  
Requirement of July 31, 2006**Page 3 of 9*RECEIVED  
CENTRAL FAX CENTER

JAN 31 2007

II. AMENDMENT TO THE CLAIMS

**COMPLETE LIST OF CLAIMS THAT ARE OR HAVE BEEN BEFORE THE  
OFFICE AFTER ENTRANCE OF THE AMENDMENTS MADE HEREIN**  
(See next page)

CTOL/IOPPFA/231705.2


PAGE 6/12 \* RCVD AT 1/31/2007 7:06:14 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-3/3 \* DNIS:2738300 \* CSID: \* DURATION (mm:ss):03-02

CHL-102(C):

*Amendment for S/N 10/790,647, responsive to Restriction  
Requirement of July 31, 2006  
Page 4 of 9*

## 1. – 10. (CANCELLED)

11. (CURRENTLY AMENDED) A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma, while optionally elevating HDL cholesterol levels comprises administering a compound of formula (I),



its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, ~~as defined in the claim 1~~ and a pharmaceutically acceptable carrier, diluent, excipients or solvate to a patient in need thereof wherein wherein one or more groups R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> may be same or different and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C<sub>1</sub>-C<sub>12</sub>)alkyl, linear or branched (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, cyclo(C<sub>3</sub>-C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, ar(C<sub>1</sub>-C<sub>12</sub>)alkoxy, heterocyclyl, heteroaryl, heterocyclyl(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroaryloxy, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkoxy, heterocyclyoxy, heterocyclalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino: alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,

CHL-102(C):

*Amendment for S/N 10/790,647, responsive to Restriction  
Requirement of July 31, 2006  
Page 5 of 9*

heterocyclalkoxycarbonyl, heteroaryloxycarbonyl, heteroaralkoxycarbonyl, heterocyclloxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, (C<sub>1</sub>-C<sub>12</sub>)alkylthio, thio(C<sub>1</sub>-C<sub>12</sub>)alkyl, arylthio, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazino, alkyl hydrazino, alkoxyamino, hydroxylamino, derivatives of sulfenyl and sulfonyl groups, carboxylic acid and its derivatives, sulfonic acid and its derivatives, phosphonic acid and its derivatives; or the adjacent groups R<sup>2</sup> and R<sup>3</sup> together may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from O, N, or S; n is an integer ranging from 1 to 8; W represents O, S or NR<sup>9</sup> where R<sup>9</sup> represents hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkyl or aryl; Ar represents a substituted or unsubstituted divalent single or fused aromatic, heteroaromatic or heterocyclic group; R<sup>5</sup> and R<sup>6</sup> represent both hydrogen or together represent a bond; R<sup>5</sup> and R<sup>6</sup> may also represent a hydroxy, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, halogen, acyl, substituted or unsubstituted aralkyl group; X represents O or S; R7 represents hydrogen, perfluoro(C<sub>1</sub>-C<sub>12</sub>)alkyl, substituted or unsubstituted groups selected from (C<sub>1</sub>-C<sub>12</sub>)alkyl, cyclo(C<sub>1</sub>-C<sub>12</sub>)alkyl, aryl, ar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroaryl, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heterocyclyl, alkoxyalkyl, aryloxyalkyl, alkoxy carbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl groups; Y represents O or S; Z represents oxygen, sulfur or NR<sup>10</sup>, where R<sup>10</sup> represents hydrogen or substituted or unsubstituted groups selected from (C<sub>1</sub>-C<sub>12</sub>)alkyl, aryl, ar(C<sub>1</sub>-C<sub>12</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>12</sub>)alkyl, amino(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroaryl, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkyl groups; R<sup>8</sup> represents hydrogen,

CHL-102(C);

*Amendment for S/N 10/790,647, responsive to Restriction  
Requirement of July 31, 2006  
Page 6 of 9*

substituted or unsubstituted groups selected from (C<sub>1</sub>-C<sub>12</sub>)alkyl, aryl, ar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroaryl, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, alkoxyalkyl, alkylaminoalkyl groups; R<sup>10</sup> and R<sup>8</sup> together may form a 5 or 6 membered substituted or unsubstituted cyclic ring structure containing carbon atoms or containing one or more heteroatoms selected from O, N and S.

**12. - 15. (CANCELLED)**

**16. (CURRENTLY AMENDED)** A method of reducing blood glucose, triglycerides, cholesterol, or free fatty acids in the plasma, comprising administering a compound as defined in the claim [[7]] 11 and a pharmaceutically acceptable carrier, diluent or excipients or solvate to a patient in need thereof.

**17. (CANCELLED)**

**18. (CURRENTLY AMENDED)** A method of preventing or treating diseases caused by ~~hyperlipidemia, hypercholesterolemia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, diabetic complications,~~ comprising administering an effective, non-toxic amount of compound of formula (I) as defined in claim [[1]] 11 to a patient in need thereof.

**19. (CURRENTLY AMENDED)** The method according to claim 18, wherein the complication is type 2 diabetes, impaired glucose tolerance, ~~dyslipidaemia, hypertension,~~

CHL-102(C):

*Amendment for S/N 10/790,647 responsive to Restriction  
Requirement of July 31, 2006  
Page 7 of 9*

~~obesity, atherosclerosis, hyperlipidaemia, coronary artery disease, cardiovascular disorders, renal diseases, microalbuminuria, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, diabetic retinopathy, diabetic nephropathy, endothelial cell dysfunction, psoriasis, polycystic ovarian syndrome (PCOS), dementia, end stage renal disease, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.~~

20. - 46. (CANCELLED)

47. (NEW) A compound according to claim 11, wherein the pharmaceutically acceptable salt is a Li, Na, Ca, Mg, lysine, arginine, guanidine and its derivatives, tromethamine, diethanolamine, choline, ammonium, substituted ammonium salts, or a aluminium salts.